• Home
• Defective Drug Index
• About A Drug Recall
• Contact A Defective Drug Lawyer

We Can Help.

Bextra® Reaction

The American Heart Association convened for their annual meeting on November 9, 2004. Among the major presentation topics was talk about the potential adverse Bextra® reaction that has been shown to occur in certain Bextra® users. A leading heart researcher at the convention announced a study revealing that patients who had recently undergone cardiac bypass surgery were more likely to experience an adverse Bextra® reaction than patients who were not taking this medication. Patients taking Bextra® were twice as likely to suffer a heart attack or stroke as patients who were not.

The New York Times published an article indicating that serious cardiovascular complications were associated with the use of Bextra® in certain patient populations. Pfizer, the pharmaceutical company who manufactures Bextra®, announced that the company has plans to conduct further research about this adverse Bextra® reaction, but that a Bextra® recall would not be considered at this time.

Patients who had undergone heart surgery in this particular trial were much more likely to experience adverse health complications as a result of a Bextra® reaction. As compared to patients not taking Bextra®, the Bextra® reaction in users included an increased occurrence of heart attack, stroke, renal failure, and wound complications. No conclusive studies have revealed cardiovascular Bextra® reaction risks in other patient groups.

Other types of serious Bextra® reaction risks have been extensively researched and well documented since this drug was first approved for use in the United States. The most common adverse Bextra® reaction symptoms include indigestion, headache, abdominal pain, nausea, and diarrhea. An adverse Bextra® reaction can also occur in patients who are concurrently taking other popular medications such as aspirin, Warfarin, and oral contraceptives. An allergic or anaphylactic Bextra® reaction is also possible in patients taking this prescription pain medication.

The most serious type of Bextra® reaction that can occur in patients involves the risk of developing serious skin conditions. An adverse Bextra® reaction can cause Stevens-Johnson syndrome or toxic epidermal necrolysis. Both of these Bextra® reaction skin conditions have led to fatality in Bextra® patients. Stevens-Johnson syndrome is a Bextra® reaction characterized by a severe inflammatory eruption of the skin and mucous membranes. A toxic epidermal necrolysis Bextra® reaction causes large portions of a patient's skin to become irritated, red, and peel much like a second degree burn would.

Because there is a significant possibility that a patient can suffer a serious adverse Bextra® reaction causing cardiovascular injury, drug interactions, allergic reactions, and severe skin conditions, patients who are taking this drug should be carefully monitored for any sign of complications. If a patient experiences any adverse Bextra® reaction symptoms they should be evaluated by a medical professional as soon as possible.

If you have been injured because of an adverse Bextra® reaction, you may wish to contact a Bextra® Lawyer who may be able to help you recover what you have lost as a result of your injuries.

More Bextra® Resources

Bextra Consumer Information - Patient FAQ on Bextra, including side effects, warnings and drug information from the FDA.